Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.15 USD | -7.18% | +3.20% | +58.69% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.69% | 1.73B | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.69% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-13-2021 05